Picard Medical Inc. (NYSE American: PMI) surged nearly 44% in pre-market trading after releasing second-quarter 2026 results that exceeded revenue expectations, despite a wider-than-anticipated loss.
The company reported revenue of approximately $2.95 million for the quarter, nearly double the consensus estimate of $1.55 million. Earnings per share came in at a loss of $3.05, exceeding the estimated loss of $1.50 per share. The stock had previously traded near its 52-week low of $2.65.
Picard Medical’s financial report was published on August 24, following the close of markets. The NYSE American accepted the company’s listing compliance plan in late July, providing an additional tailwind to investor sentiment.
The company also issued a fresh investor presentation under Regulation FD to bolster its capital markets outreach. The broader U.S. equity market showed little movement, with the S&P 500 down 0.1%, the Nasdaq declining 0.6%, and the Dow essentially flat.
